Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gedeon Richter PLC (RGEDF)
Budapest, BC, HU
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.89% | -9.64% | -12.22% | +28.22% | +28.55% | +28.22% | +46.30% | +82.25% | +36.43% | +164.95% | +108.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Pharmaceuticals: +7.8%+7.7% Q1'26: -1.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-3.3% Q1'26: -4.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+19.2% Q1'26: +35.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+34.9% ★ Q1'26: +32.3% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+22.4% ★ Q1'26: +20.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.1% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.09× ★ Q1'26: 0.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 1 EPS Ana. |
Dec 2027 6 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
365.22B
est: 361.35B (+1.1%)
|
389.69B
est: 389.45B (+0.1%)
|
444.36B
est: 456.64B (-2.7%)
|
445.48B
est: 403.08B (+10.5%)
|
507.79B
est: 472.78B (+7.4%)
|
566.78B
est: 544.95B (+4.0%)
|
630.60B
est: 602.80B (+4.6%)
|
802.76B
est: 769.25B (+4.4%)
|
805.16B
est: 792.47B (+1.6%)
|
857.55B
est: 855.84B (+0.2%)
|
923.40B
est: 911.21B (+1.3%)
|
1.07T
1.03T – 1.11T
+17.3% YoY
|
1.16T
1.12T – 1.21T
+8.1% YoY
|
1.24T
1.20T – 1.29T
+7.4% YoY
|
1.29T
1.25T – 1.35T
+4.3% YoY
|
1.16T
1.12T – 1.21T
-10.6% YoY
|
| EBITDA |
92.29B
est: 112.74B (-18.1%)
|
101.95B
est: 121.51B (-16.1%)
|
49.64B
est: 142.47B (-65.2%)
|
78.86B
est: 125.76B (-37.3%)
|
90.76B
est: 147.51B (-38.5%)
|
155.64B
est: 170.02B (-8.5%)
|
192.16B
est: 188.07B (+2.2%)
|
222.26B
est: 240.00B (-7.4%)
|
262.59B
est: 247.25B (+6.2%)
|
342.57B
est: 294.54B (+16.3%)
|
381.88B
est: 313.60B (+21.8%)
|
367.77B
355.38B – 381.95B
+17.3% YoY
|
397.59B
383.83B – 416.29B
+8.1% YoY
|
426.87B
412.28B – 445.21B
+7.4% YoY
|
445.07B
429.86B – 464.19B
+4.3% YoY
|
398.06B
384.45B – 415.16B
-10.6% YoY
|
| EBIT |
61.04B
est: 90.91B (-32.9%)
|
69.05B
est: 97.98B (-29.5%)
|
14.89B
est: 114.89B (-87.0%)
|
43.96B
est: 101.41B (-56.7%)
|
51.44B
est: 118.95B (-56.8%)
|
115.80B
est: 137.11B (-15.5%)
|
147.24B
est: 151.66B (-2.9%)
|
173.69B
est: 193.54B (-10.3%)
|
187.08B
est: 199.38B (-6.2%)
|
293.05B
est: 241.28B (+21.5%)
|
321.78B
est: 256.89B (+25.3%)
|
301.27B
291.11B – 312.89B
+17.3% YoY
|
325.69B
314.42B – 341.01B
+8.1% YoY
|
349.68B
337.73B – 364.70B
+7.4% YoY
|
364.59B
352.13B – 380.25B
+4.3% YoY
|
326.08B
314.93B – 340.08B
-10.6% YoY
|
| Net Income |
53.86B
est: 47.82B (+12.6%)
|
66.20B
est: 63.92B (+3.6%)
|
8.89B
est: 64.14B (-86.1%)
|
35.35B
est: 57.81B (-38.9%)
|
47.14B
est: 67.45B (-30.1%)
|
104.68B
est: 99.98B (+4.7%)
|
139.63B
est: 116.79B (+19.6%)
|
169.08B
est: 204.35B (-17.3%)
|
158.85B
est: 169.60B (-6.3%)
|
239.24B
est: 237.46B (+0.8%)
|
230.94B
est: 228.11B (+1.2%)
|
280.13B
267.68B – 295.77B
+22.8% YoY
|
311.51B
297.67B – 328.91B
+11.2% YoY
|
346.57B
331.17B – 365.93B
+11.3% YoY
|
358.07B
342.16B – 378.07B
+3.3% YoY
|
219.97B
210.20B – 232.25B
-38.6% YoY
|
| SGA |
117.71B
est: 86.16B (+36.6%)
|
127.90B
est: 92.86B (+37.7%)
|
138.26B
est: 108.89B (+27.0%)
|
139.65B
est: 96.11B (+45.3%)
|
150.80B
est: 112.74B (+33.8%)
|
133.77B
est: 129.94B (+2.9%)
|
143.26B
est: 143.74B (-0.3%)
|
182.35B
est: 183.43B (-0.6%)
|
196.62B
est: 188.96B (+4.1%)
|
220.99B
est: 204.73B (+7.9%)
|
221.46B
est: 217.98B (+1.6%)
|
255.63B
247.01B – 265.49B
+17.3% YoY
|
276.36B
266.79B – 289.35B
+8.1% YoY
|
296.70B
286.56B – 309.45B
+7.4% YoY
|
309.35B
298.78B – 322.64B
+4.3% YoY
|
276.68B
267.22B – 288.57B
-10.6% YoY
|
| EPS |
291.00
est: 261.30 (+11.4%)
|
356.00
est: 349.27 (+1.9%)
|
48.00
est: 350.47 (-86.3%)
|
189.72
est: 315.85 (-39.9%)
|
253.40
est: 368.55 (-31.2%)
|
562.90
est: 546.31 (+3.0%)
|
750.65
est: 638.11 (+17.6%)
|
834.96
est: 1,116.56 (-25.2%)
|
859.72
est: 926.71 (-7.2%)
|
1,307.00
est: 1,299.01 (+0.6%)
|
1,263.79
est: 1,247.91 (+1.3%)
|
1,532.46
1,464.37 – 1,618.04
+22.8% YoY
|
1,704.15
1,628.43 – 1,799.32
+11.2% YoY
|
1,895.93
1,811.70 – 2,001.82
+11.3% YoY
|
1,958.84
1,871.81 – 2,068.23
+3.3% YoY
|
1,203.35
1,149.89 – 1,270.56
-38.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-01 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gabor Orban | CEO & Director | 165M | male |
| Laszlo Andras Kovacs | Group Head of Controlling, Chief Financial Officer & Director | 89M | male |
| Katalin Erdei | Human Resources & Technical Director | — | female |
| Robert Rethy | Head of the Investor Relations & ESG Department | — | male |
| Tamas Szolyak | Director of Global Regulatory Science, Commerce & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RGEDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
